Alnylam Pharmaceuticals (ALNY) Depreciation & Amortization (CF) (2009 - 2018)

Alnylam Pharmaceuticals (ALNY) has 10 years of Depreciation & Amortization (CF) data on file, last reported at $3.2 million in Q1 2018.

• Quarterly Depreciation & Amortization (CF) rose 5.93% year-over-year to $3.2 million in Q1 2018, while the trailing twelve-month figure through Dec 2018 was $3.2 million (down 76.23% YoY) and the FY2025 annual result came in at $54.8 million, down 0.54% from the prior year.
• Depreciation & Amortization (CF) slipped to $3.2 million in Q1 2018, from $3.7 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.3 million in Q3 2015 to a low of $2.6 million in Q1 2014.
• A 5-year average of $3.7 million and a median of $3.5 million in 2016 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2015 — Depreciation & Amortization (CF) surged 75.07% — and 2016, when it sank 40.46%.
• Tracing ALNY's Depreciation & Amortization (CF) over 5 years: stood at $3.3 million in 2014, then jumped by 51.72% to $5.1 million in 2015, then slumped by 40.46% to $3.0 million in 2016, then advanced by 23.06% to $3.7 million in 2017, then slipped by 14.43% to $3.2 million in 2018.
• The last three Depreciation & Amortization (CF) figures came in at $3.2 million (Q1 2018), $3.7 million (Q4 2017), and $3.6 million (Q3 2017), per Business Quant data.